Eduardo Vilar-Sanchez

iCAN PREVENT: MD Anderson International Cancer Prevention Clinical Trials Consortium

National Cancer Institute · UG1

Contact PI · $10.5M · University of Tx Md Anderson Can Ctr

Assessment of Immune Responses to Neoantigen Vaccination in Lynch Syndrome

National Cancer Institute · R01

Contact PI · $696.9K · University of Tx Md Anderson Can Ctr

Project Title: Low-Dose Erlotinib and Mesalamine for Prevention of Colitis-Associated Colorectal Cancer (CAC)

NIH Office of the Director · N01

Contact PI · $1.9M · University of Tx Md Anderson Can Ctr

Immunoepigenetic Targeting of MHC Regulators in FAP

National Cancer Institute · R01

PI · $2.3M · Texas A&m University Health Science Ctr

A Phase IIa Randomized, Double-Blinded Clinical Trial of Naproxen or Aspirin for Cancer Immune Interception in Lynch Syndrome

Principal investigator · Recruiting · Phase 2

M.D. Anderson Cancer Center

Testing Obeticholic Acid for Familial Adenomatous Polyposis

Principal investigator · Terminated · Phase 2

National Cancer Institute (NCI)

Cancer Preventive Vaccine Nous-209 for Lynch Syndrome Patients

Principal investigator · Active not recruiting · Phase 1, Phase 2

National Cancer Institute (NCI)

Cycling in Preventing Colorectal Cancer in Participants With Lynch Syndrome

Principal investigator · Completed

M.D. Anderson Cancer Center